secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kalaris Therapeutics, Inc. (KLRS)
CIK:        0001754068
Form:       8-K
Filed at:   2024-12-20T23:59:59+00:00
Accession:  0001193125-24-283140
Event type: leadership
Sentiment:  neutral
Materiality: 0.65
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CEO Diana Brainard departs; President/CFO Vikas Sinha named CEO effective Dec 19, 2024
--------------------------------------------------------------------------------

- Diana Brainard resigned as CEO and director effective Dec 19; no disagreement with company on operations, policies, or practices.
- Vikas Sinha (President, CFO since 2019) appointed CEO and principal executive officer same day; he has over 20 years life sciences finance experience.
- Brainard receives $1.88M lump sum (36-mo salary), $376k target bonus, $100k merger completion bonus, and acceleration of 371,525 RSUs.
- Company previously disclosed proposed merger with Kalaris Therapeutics, Inc.; Sinha served as CFO of Alexion Pharma (ALXN) previously.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1754068/000119312524283140/0001193125-24-283140-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1754068/000119312524283140/d905140d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-283140

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer